Introduction
Carcinoma of an unknown primary site (CUP) accounts for 0.5%-10% of all adult malignancies [1] . CUP is defined as metastatic epithelial cancer with no identified primary. Such lesions can now be diagnosed more accurately due to recent progress in histopathology and imaging. Experience during the last 20 years has indicated that treatment of this particularly heterogeneous entity should not be uniform and limited to a single treatment modality [2] . A number of subgroups, based on the clinical presentation and pathological findings, have been identified for which specific therapy is recommended [2, 3] . These subgroups include peritoneal papillary adenocarcinoma in women [4] , isolated axillary lymph node metastasis from an adenocarcinoma in women [5] , cervical lymph node metastases from squamous-cell carcinoma, middle-line undifferentiated carcinoma in young patients [6] and poorly-differentiated neuro-endocnne carcinoma [7] . Nevertheless, about 85% of CUP patients do not fit into these subgroups, but are usually treated as a single group whose disease, although multifaceted, is considered eligible for the same treatment and drugs (reviewed in [2] ). In this case, these neoplasms are usually deemed moderately chemosensitive and the prognosis remains poor, with a median survival ranging from 6-10 months in most reports [8] [9] [10] .
Prospective studies investigating the activity of single agents remain few and far between Only a few randomized studies have tried to define the role of combination therapies versus single agents [9] or combinations containing cisplatin [8] [9] [10] .
In many reports [12, 13] and in our own experience, poorly-differentiated carcinomas (PDC) and undifferentiated carcinomas (UDC) were found to be more chemosensitive than well-and moderately-well-differentiated carcinomas (WDC/MDC). Response rates attained 50% in the former. This distinct difference in chemosensitivity was the rationale underlying the design of a histologically-adapted chemotherapy strategy in patients with CUP. The main objective of this study was to achieve higher response rates and thereby enhance the efficacy of chemotherapy in each subgroup of patients Patients with PDC/UDC were initially scheduled to receive two cycles of the cisplatin-etoposide combination based on high response rates reported with this combination in this subgroup In order to enlarge the chemotherapy-targeted tumor spectrum, and as some PDC and UDC were reported to be in fact undifferentiated lymphomas, germ-cell tumors [14] or neuroendocnne carcinomas [7] , lfosfamide and bleomycin were added to cisplatin and etoposide from the third cycle onwards for responsive or stable disease. In the second group of patients with WDC and MDC, the chemo-therapy strategy was based on the administration of continuous infusion 5-FU, in order to circumvent the usual chemoresistance of these slowly growing neoplasms [15] . Cisplatin was used in combination with continuous 5-FU based on the synergy between these two drugs [16] and with the objective of broadening the tumor spectrum. Alpha-interferon was also included in this combination because prechnical studies indicated that a-interferon exerted modulatory effects on 5-FU [17] and because promising results were reported with this combination in colo-rectal cancer just as this study was about to begin [18] We report here the final analysis of this study were repeated every three weeks Patients were reassessed after the first two courses responders and patients with stable lesions received four additional courses According to the protocol, treatment delays and dose modifications were based on complete blood counts taken on the day of planned next treatment, as well as any grade 3-4 toxicity occurring at any time during therapy For retreatment, it was necessary for any toxicity to have settled down to a minimum grade I Treatment was delayed until granulocyte count reached a minimum of >1500/ul and platelets reached a minimum of >IOO,000/ul A new course was also only initiated if serum creatimne was less than 150 umol/1 or the creatinine clearance was more than 50 ml/min The total dose of each drug (except alpha-2b interferon) was reduced by 25% if grade 3-4 organ-specific toxicity occurred on the previous cycle Treatment was discontinued if any other life-threatening loxicity occurred or on patient request
Patients and methods

Patients
This study was performed at the Institut Guslave Roussy, Villejuif. France from October 1993 to October 1998, after approval by the regional ethical committee on human experimentation
Patients with histologically-confirmed metastatic carcinoma of an unknown primary site were prospectively included and registered Patients who had previously been treated with chemotherapy were ineligible The histological diagnosis of carcinoma was obtained for all the patients and outside slides were reviewed in our center Patients were included if the following work-up did not reveal a primary tumor complete clinical examination, chest X-ray, computed tomography of the abdomen, serum tumor marker measurement (alpha feto-protein, human chonogonadotropin, prostate specific antigen) along with a radiologic work-up depending on the metastatic sites and symptomatic areas Patients with CUP in a subgroup known to respond to therapy or to specific treatments were excluded
The histological diagnosis was performed with routine light microscopy and immunocytochemistry and reviewed by a panel of pathologists specialized in oncology The tumors were classified according lo the degree of differentiation for each tumor category (adenocarcinoma or carcinoma) inlo Ihe following subsets well-differentiated, moderately-differentiated, poorly-differentiated, undifferentiated and undetermined (based on light microscopic morphologic features, as the degree of formation of glandular structures by neoplastic cells for adenocarcinomas) Specific pathological tests were performed according to the clinical presentation and histologic features immunopero.xydase staining for leukocyte common antigen, neuroendocnne cell markers, melanoma cell markers, prostate specific antigen, germ-cell markers (HCG. AFP). Carcinoma Embryonic Antigen (CEA)
Treatment
Patients with poorly-differentiated adenocarcinoma or carcinoma (PDA/PDC) (group A) received a combination of cisplatin (20 mg/m 2 /day) on days 1-5 and etoposide (100 mg/m 2 /day) on days 1-5 Patients older than 60 years or with a performance status equal to 2 were given a simplified schedule cisplatin (100 mg/m 2 ) on day 1 and etoposide (100 mg/m 2 /day) on days 1-3 Treatment was administered at three-week intervals Patients with a good performance status and a responsive or stable disease after two cycles were selected to receive the same regimen plus bleomycin (60 mg bolus) on day 1 followed by 10 mg/day on days 1-5 and ifosfamide (800 mg/m 2 /day) on days 1-5, in combination with mesna. plus G-CSF (5 ug/kg/day) for eight days (1BEP)
Patients with well-or moderately-differentiated adenocarcinoma (group B) were enrolled to receive cisplatin (80 mg/m 2 ) on day I, 5-FU (250 mg/m 2 /day) on days 1-21 in a continuous infusion and a-interferon (3 \0 h Ul/day) subcutaneously on days 1-4 Alpha-2b interferon was kindly provided by Dr Laurence Thill (Roche. France) Cycles Evaluation criteria Toxicity was scored after each cycle using ECOG criteria
Response was assessed every two cycles by repeating the initial work-up Complete remission was defined as the complete disappearance of all clinically and radiologically detectable disease Partial remission was defined as at least a 50% reduction in the size of all measurable lesions Disease was considered stable in the absence of response and progression and without the appearance of new lesions Progressive disease was defined as an increase of more than 25% in the size of any lesion or the appearance of a new lesion Patients were then monitored at regular intervals during follow-up. When tumor progression occurred, treatment was at the discretion of the physician All treated patients were considered evaluable for toxicity and response Only major dose-intensity violations modifications ( > 10%) were taken into account to simplify the analysis Overall survival was measured from the first day of treatment to the last follow-up visit or to the time of death The duration of response was measured from the first day of therapy until tumor progression Survival curves were estimated using the Kaplan and Meier method and compared using the log-rank test
Results
Patient characteristics
Between November 1993 and October 1998, 48 consecutive patients were enrolled in the study Patient characteristics are listed in Table 1 The liver was the main site of disease in group B. Disease was mostly located at multiple sites or in lymph nodes in patients with poorlydifferentiated tumors (group A). In any case, whatever the metastatic sites, patients never had a single metastasis. The performance status was typically good in both groups
Therapy
Thirty patients (62 5%) had PDC/PDA (group A) and received the cisplatin-etoposide (EP) combination. Nine of these patients in whom disease was considered responsive or stable after two courses were selected to receive the intensified IBEP regimen. The 18 remaining patients (37.5%) had well-or moderately-differentiated adenocarcinoma (group B) and received the cisplatin, 5-FU and a-interferon combination (PFI) Overall, dose-intensity was usually maintained: all except one patient received at least two courses of therapy. This patient received only one course of therapy because of cardiac failure after the first cycle. Major dose modifications seldom occurred in the EP treated group in 4 out of 30 cases, treatment was delayed due to low blood cell counts. The median number of EP cycles/patient was three (range 1-7) and nine patients subsequently received a median number of four intensified cycles (range 1-6). The 18 patients in group B received a median number of 5 cycles (range 2-8) of the PFI combination. There were 7 major dose modifications involving 5-FU or a-interferon, due to skin toxicity or fatigue.
Response
Of 48 patients, 46 were evaluable for response Two patients could not be assessed for response due to early death (in one case due to cardiac failure and the other patient, who was in a very poor general condition with obvious disease progression, died after two cycles of therapy before the objective evaluation of response). Overall, 13 of 48 patients (27%) achieved a complete response after the completion of therapy whereas 7 (15%) had a partial response. By intent-to-treat analysis, the overall response rate is 43% (95% CI 35.9%-50 1%). In 12 patients (25%) disease remained stable and in 14 (30%) it progressed. Details on response to therapy according to patient subgroups are summarized in Table 2 Although the objective response rates are similar in both histologicallydefined subgroups, at respectively 40 % (95% CI: 31.1%-48 9%) and 44% (95% CI: 32.3%-55.7%), it is noteworthy that the group of patients who received the PFI combination achieved a high rate of complete responses (33%)
Survival
Median survival was 13 3 months (95% CI: 8.4-18.2 months) and two-year survival was 33%. Median survival was 9.4 months (95% CI 5-13 7 months) in group A and 16.1 months (95% CI 11 8-20.3 months) in group B (PFI regimen), and two-year overall survival rates were 28% and 39%, respectively (Figure 1) .
Median progression-free survival (PFS) in the group of patients with WDC/MDC was similar to the median PFS in the group with PDA/PDC, namely 8.6 months (95% CI: 1.5-15.8 months) and 8.1 months (95% CI. 4.3-12 months), respectively With a median follow-up of 32 months, 13 patients (27%) are alive and progression-free more than 20 months after the initiation of treatment. Six out of these patients had multiple peripheral lymph nodes (negative on immunohistochemical staining with LCA) but no visceral metastases. Thus far, 9 primaries have been identified during follow-up (19%): lung cancer (3), breast cancer (2), ovarian cancer (1), carcinoma of the maxillary gland (1) and mesothelioma (1) . No autopsy was performed Toxicity Myelosuppression, the most common toxicity, was moderate in most patients. Only three patients (14%) developed neutropenic fever and required hospitalization whereas only one (5%) required a blood transfusion. One patient died of cardiac failure after the first cycle the EP combination This 59-year-old patient presented initially with multiple sites of disease and a poor performance status.
As expected, myelosuppression was also very common in patients who received the IBEP regimen, despite GCSF, but none had neutropenic fever. Transfusions were nevertheless necessary Treatment had to be stopped in one patient after the first cycle containing bleomycin due to skin toxicity, major changes in respiratory tests along with clinical symptoms and grade 4 hematologic toxicity. Three other patients experienced deterioration of their respiratory function on tests without any clinical symptoms.
In patients who received the PFI regimen, hand-foot syndrome and 5-FU-related diarrhea were the two major adverse effects requiring dose reduction in four and two cases, respectively Alpha-interferon was stopped in three cases due to major fatigue
Discussion
Major progress has yet to be achieved in the treatment of patients with carcinoma of an unknown primary site. If the patient does not belong to one of the previouslydefined subsets, the prognosis remains very poor although various regimens have been attempted [2, 3] . A better understanding of the natural history of this heterogeneous entity and of the prognostic factors may shed light on relevant diagnostic and treatment approaches. New strategies are still needed and the availability of new agents offers hope of improving future results.
Thus far, well-differentiated adenocarcinoma have responded poorly to many combination chemotherapy regimens [8] [9] [10] [19] [20] [21] In contrast, there are many reports of better response rates in poorly-differentiated carcinoma/adenocarcinoma [12, 22] . The response rate with the cisplatin-etoposide combination was reported to attain 63% with median survival peaking at about 12 months, and this regimen is recognized as one of the best therapeutic options for this disease by many investigators, although not unanimously considered the gold standard [12] Surprisingly, this two-tailed response profile was not found in a recent report on a promising therapeutic regimen combining paclitaxel, carboplatin and etoposide. overall response rates were 45% and 48%, respectively, in the two subgroups and survival curves overlapped [11] . Median survival was 13.4 months, whatever the degree of tumor differentiation
The best results achieved to date for well-differentiated carcinomas/adenocarcinomas are those mentioned above, that were reported by Hainsworth and Greco [11] , and those we achieved with the cisplatin-5-FUmterferon combination. In our study, the duration of median survival was 16.1 months with an objective response rate of 44%. No treatment-related death occurred, and the major toxic effect was 5-FU-related hand-foot syndrome. These results compare favorably with those previously reported on this histological subtype [8, 9, [19] [20] [21] . Previous 5-FU-containing regimens yielded the typical 30% response rates and only permitted short-term survival [3] We decided to choose the continuous infusion 5-FU schedule, instead of a short infusion for several reasons. Firstly, a high cumulative dose can be safely delivered and studies have suggested an improvement of response rates and decreased toxicity in advanced colorectal cancer [15] using this mode of administration. Moreover, drug activity is maintained over a long period of time and this may prove useful for a slowly-prohferatmg metastatic disease such as differentiated adenocarcinoma Secondly, the activity of 5-FU has been shown to be synergistic with that of cisplatin both in vitro and in vivo [23] and in the clinic However, the adjunction of cisplatin to chemotherapy regimens failed to improve the survival of patients with CUP in previous trials, although response rates reported were generally better than that of other regimens [12] . Interferon was added based on an alleged synergistic effect when associated with 5-FU [18] . Unfortunately, recently published trials have not confirmed any benefit in colo-rectal cancer [24, 25] Basically, we believe that the cisplatin and 5-FU combination given alone as a continuous infusion is probably just as effective.
In the PDA/PDC group, our results are comparable to those usually described with the EP combination: the median duration of survival was 9.4 months and a 40% objective response rate was attained. They are also in the range of those previously reported by other investigators with this regimen [2, 13] In order to improve the response rate and the duration of responses, we intensified this regimen in responders This was based on the dose-effect theory in oncology. The two drugs chosen to intensify the cisplatin-etoposide regimen were bleomycin and lfosfamide because I) their mechanisms of action are different from those of the former agents, ii) their activity in germ-cell tumors is well-known, in) patients with the 'unrecognized extragonadal germ-cell cancer syndrome' [12] are considered potentially curable, IV) germ-cell tumors are sometimes difficult to differentiate from PDC, although a meticulous histological examination was systematically performed with immunohistochemical studies to exclude this entity. However no cytogenetic analysis was performed to detect the il2p chromosomal abnormality. Nine patients in this series were selected for this intensification strategy Only two of them are still alive and most patients died a few months after the first signs of progression despite second-line chemotherapy, indicating that this regimen might select aggressive, chemoresistant clones. The real impact of the intensification strategy for CUP therefore remains to be demonstrated.
A step forward has been achieved in the treatment of patients with CUP with the identification of subgroups of patients with clinical and histological features that may respond to treatment [2] [3] [4] [5] [6] [7] Whether patients should be treated according to histological differentiation or not if they do not enter one of these categories, is still a subject of debate [11] . There is a clear controversy regarding a difference in responsiveness between poorly differentiated carcinomas and well-differentiated adenocarcinomas. Our data suggest that both group may be relatively responsive and this may be a factor of which chemotherapy they receive or a function of the various prognostic factors known to be at play in these patients. Only a randomized prospective trial, stratified upon histological differentiation, could address this issue. The cisplatin, etoposide ± bleomycin combination is considered one of the best options in PDA/PDC, and this is confirmed by our trial. More active treatments have recently emerged for well-or moderately-welldifferentiated tumors' the cisplatin-5-FU continuous infusion combination described here and the paclitaxel-carboplatin and extended-schedule etoposide combination reported by Hainsworth et al. [11] . Hospitalization is required for the delivery of cisplatin in the former whereas the latter combines more expensive drugs.
The activity of other regimens, comprising new drugs demonstrated to be effective in a wide spectrum of neoplasms, will need to be investigated in CUP in the future, particularly as these responsive neoplasms include lung cancer and GI tract carcinomas that are well known to be over-represented among occult CUP [26] Gemcitabine, irinotecan and taxanes seem to be good candidates for such regimens. Alternatively, new strategies could be based on drug screening m vitro, performed on CUP of varied degrees of differentiation. The biology of these tumors is a recently explored investigational domain [27, 28] : oncogenes and proteins determining the particular metastatic profile of these tumors, if identified, could be targets for different treatment procedures
